Purinergic receptors involved in the immunomodulatory effects of ATP in human blood

Biochemical and Biophysical Research Communications

Volumn 348, Issue 3, 2006, Pages 1194-1199

  Swennen, Els L R ^a   Bast, Aalt ^a   Dagnelie, Pieter C ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

ATP; IL 10; Inflammation; Purinoreceptors; TNF

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; INTERLEUKIN 10; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PURINE P2 RECEPTOR; PURINE RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DEFICIENCY; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; NORMAL HUMAN; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; RECEPTORS, PURINERGIC; RECEPTORS, PURINERGIC P2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33747175733     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.07.177     Document Type: Article

References (34)

1. Reimold A.M. New indications for treatment of chronic inflammation by TNF-alpha blockade. Am. J. Med. Sci. 325 (2003) 75-92
2. Atzeni F., Sarzi-Puttini P., Doria A., Iaccarino L., and Capsoni F. Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. Autoimmun. Rev. 4 (2005) 144-152
3. Crum N.F., Lederman E.R., and Wallace M.R. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 84 (2005) 291-302
4. Bakleh M., Tleyjeh I., Matteson E.L., Osmon D.R., and Berbari E.F. Infectious complications of tumor necrosis factor-alpha antagonists. Int. J. Dermatol. 44 (2005) 443-448
5. Swennen E.L., Bast A., and Dagnelie P.C. Immunoregulatory effects of adenosine 5′-triphosphate on cytokine release from stimulated whole blood. Eur. J. Immunol. 35 (2005) 852-858
6. Di Virgilio F., Chiozzi P., Ferrari D., Falzoni S., Sanz J.M., Morelli A., Torboli M., Bolognesi G., and Baricordi O.R. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 97 (2001) 587-600
7. Burnstock G., and Knight G.E. Cellular distribution and functions of P2 receptor subtypes in different systems. Int. Rev. Cytol. 240 (2004) 31-304
8. Ferrari D., La Sala A., Chiozzi P., Morelli A., Falzoni S., Girolomoni G., Idzko M., Dichmann S., Norgauer J., and Di Virgilio F. The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine release. FASEB J. 14 (2000) 2466-2476
9. Ralevic V., and Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50 (1998) 413-492
10. Hasko G., and Cronstein B.N. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 25 (2004) 33-39
11. Sitkovsky M.V. Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem. Pharmacol. 65 (2003) 493-501
12. El-Tayeb A., Griessmeier K.J., and Muller C.E. Synthesis and preliminary evaluation of [3H]PSB-0413, a selective antagonist radioligand for platelet P2Y12 receptors. Bioorg. Med. Chem. Lett. 15 (2005) 5450-5452
13. Weyler S., Hayallah A.M., and Muller C.E. Versatile, convenient synthesis of pyrimido[1,2,3-cd]purinediones. Tetrahedron 59 (2003) 47-54
14. Sauer R., Maurinsh J., Reith U., Fulle F., Klotz K.N., and Muller C.E. Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists. J. Med. Chem. 43 (2000) 440-448
15. Hockemeyer J., Burbiel J.C., and Muller C.E. Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. J. Org. Chem. 69 (2004) 3308-3318
16. Ozola V., Thorand M., Diekmann M., Qurishi R., Schumacher B., Jacobson K.A., and Muller C.E. 2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors. Bioorg. Med. Chem. 11 (2003) 347-356
17. Burbiel J.C., Thorand M., and Muller C.E. Improved, efficient synthesis for multigram-scale production of PSB-10, a potent antagonist at human A3 adenosine receptors. Heterocycles 60 (2003) 1425-1432
18. Hayallah A.M., Sandoval-Ramirez J., Reith U., Schobert U., Preiss B., Schumacher B., Daly J.W., and Muller C.E. 1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists. J. Med. Chem. 45 (2002) 1500-1510
19. Abo-Salem O.M., Hayallah A.M., Bilkei-Gorzo A., Filipek B., Zimmer A., and Muller C.E. Antinociceptive effects of novel A2B adenosine receptor antagonists. J. Pharmacol. Exp. Ther. 308 (2004) 358-366
20. von Kugelgen I., and Wetter A. Molecular pharmacology of P2Y-receptors. Naunyn Schmiedebergs Arch. Pharmacol. 362 (2000) 310-323
21. Communi D., Janssens R., Suarez-Huerta N., Robaye B., and Boeynaems J.M. Advances in signalling by extracellular nucleotides. the role and transduction mechanisms of P2Y receptors. Cell. Signal. 12 (2000) 351-360
22. Burnstock G., and Williams M. P2 purinergic receptors: modulation of cell function and therapeutic potential. J. Pharmacol. Exp. Ther. 295 (2000) 862-869
23. Communi D., Robaye B., and Boeynaems J.M. Pharmacological characterization of the human P2Y11 receptor. Br. J. Pharmacol. 128 (1999) 1199-1206
24. Khakh B.S., Burnstock G., Kennedy C., King B.F., North R.A., Seguela P., Voigt M., and Humphrey P.P. International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol. Rev. 53 (2001) 107-118
25. North R.A. Molecular physiology of P2X receptors. Physiol. Rev. 82 (2002) 1013-1067
26. Fredholm B.B., AP I.J., Jacobson K.A., Klotz K.N., and Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53 (2001) 527-552
27. Muller C.E. Medicinal chemistry of adenosine A3 receptor ligands. Curr. Top. Med. Chem. 3 (2003) 445-462
28. Marteau F., Le Poul E., Communi D., Labouret C., Savi P., Boeynaems J.M., and Gonzalez N.S. Pharmacological characterization of the human P2Y13 receptor. Mol. Pharmacol. 64 (2003) 104-112
29. Brunschweiger A., and Muller C.E. P2 receptors activated by uracil nucleotides-an update. Curr. Med. Chem. 13 (2006) 289-312
30. Communi D., Govaerts C., Parmentier M., and Boeynaems J.M. Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J. Biol. Chem. 272 (1997) 31969-31973
31. van der Weyden L., Adams D.J., Luttrell B.M., Conigrave A.D., and Morris M.B. Pharmacological characterisation of the P2Y11 receptor in stably transfected haematological cell lines. Mol. Cell. Biochem. 213 (2000) 75-81
32. Conigrave A.D., Fernando K.C., Gu B., Tasevski V., Zhang W., Luttrell B.M., and Wiley J.S. P2Y(11) receptor expression by human lymphocytes: evidence for two cAMP-linked purinoceptors. Eur. J. Pharmacol. 426 (2001) 157-163
33. + T lymphocytes. J. Immunol. 169 (2002) 15-21
34. Haraguchi S., Good R.A., and Day N.K. Immunosuppressive retroviral peptides: cAMP and cytokine patterns. Immunol. Today 16 (1995) 595-603